Market Cap : 2.03 B | Enterprise Value : 23.8 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2022-08-11), Bausch Health's Intrinsic Value: Projected FCF is $33.61. The stock price of Bausch Health is $5.65. Therefore, Bausch Health's Price-to-Intrinsic-Value-Projected-FCF of today is 0.2.
The historical rank and industry rank for Bausch Health's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Bausch Health was 11.53. The lowest was 0.15. And the median was 0.76.
The historical data trend for Bausch Health's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Intrinsic Value: Projected FCF distribution charts can be found below:
* The bar in red indicates where Bausch Health's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Bausch Health's Free Cash Flow(6 year avg) = $1,290.24.
Bausch Health's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Mar22) | / | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | 1290.24 | + | -216 | / | 0.8) | / | 360.800 | |
= | 33.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Bausch Health's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 5.65 | / | 33.296946904594 | |
= | 0.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Bausch Health's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Carson Seana | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807 |
Vadaketh Tom George | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY YARDLEY PA 19067 |
Mulligan Richard | director | C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153 |
Munsch Frederick | officer: SVP, Controller and CAO | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Gordon Joseph F | officer: Pres&Co-Head Bausch&Lomb/Int'l | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Ackermann Christina | officer: EVP AND GENERAL COUNSEL | C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Spurr Robert | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Eldessouky Sam | officer: EVP & Chief Financial Officer | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Miller Steven D | director | 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160 |
Icahn Brett | director | C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160 |
Paulson John | director | 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036 |
Valueact Holdings Ii, L.p. | director, other: See Remarks | ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129 |
Von Eschenbach Andrew C. | director | BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Mckenna Mark C. | officer: President, Salix | 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 |
Humphries William D. | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 |
From GuruFocus
Other Sources
By Zacks 2022-01-24
By Zacks 2022-03-10
By Zacks 2022-01-14
By Zacks 2022-02-07
By Zacks 2022-03-15
By Zacks 2022-02-08
By Zacks 2022-01-21
By Zacks 2022-01-19
By tipranks.com 2022-02-23
By Zacks 2022-03-25
By Zacks 2022-03-30
By Zacks 2022-01-31
By Zacks 2022-02-21